Related Experiment Video
Updated: Feb 12, 2026

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
Published on: February 24, 2014
Bioinformatic evaluation of ClpP as a vaccine target in Streptococcus pneumoniae
Yanying Huang1, Liyan Zhu1, Weihua Li2
1Department of Pathology, Hangzhou Red Cross Hospital, Hangzhou, 310003, Zhejiang, China.
Purpose:
To conduct a comprehensive bioinformatic analysis to assess the immunogenicity and conservation profiles of ClpP in Streptococcus pneumoniae, thereby verifying its feasibility as a candidate vaccine target.
Methods:
The nucleotide and amino acid sequences of the clpP gene were obtained from the NCBI database. The fundamental characterizations of ClpP were retrieved from the public database PneumoWiki. NetPhos was used to predict phosphorylation sites, whereas SOPMA, Swiss-Model and STRING were employed to analyze secondary/tertiary structures and functional interaction network, respectively. Antigenic epitope mapping was carried out using DNASTAR, SYFPEITHI, NetMHCIIpan 4.0 and NetMHC. Multiple sequence alignment (MSA) was performed using Jalview software to analyze the conservation of the predicted epitopes across S. pneumoniae strains. Concurrently, a phylogenetic tree was constructed to evaluate the cross-species conservation of the ClpP protein.
Results:
ClpP (196 aa, pI 4.74) showed high hydrophobicity and without signal peptides/transmembrane domains. Phosphorylation sites (Ser/Thr/Tyr) were identified. The secondary structure of ClpP consists of 94 α-helices, 37 β-strands and 65 random coils. The functional interaction network of ClpP involves 10 interacting partners. Immunoinformatic analysis further detected immunodominant B-cell and T-cell epitopes within the ClpP sequence.
Conclusion:
Taken together, these data suggest that ClpP exhibits robust immunogenicity and multiple antigenic epitopes, supporting its potential as a peptide-based vaccine candidate against S. pneumoniae.
Related Concept Videos
Vaccinations
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....

